Compare Oscar Health Inc (OSCR) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance

Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.

The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.

SPYI (NEOS S&P 500 High Income ETF) trades at $53.01, down 0.11% with a bearish technical signal. The fund has grown to over $10 billion in assets under management and delivers consistent monthly distributions through its covered call strategy. Recent performance shows 8% year-to-date and 19% one-year returns, though trailing the broader S&P 500. The ETF's two-leg options strategy enables robust income generation while retaining partial upside exposure.

SPYI offers investors high-yield income with downside protection, making it attractive for retirement portfolios. However, the fund's 0.68% expense ratio and potential return of capital distributions require careful consideration. Market volatility benefits the options strategy, but sustained bull markets may limit upside participation compared to traditional index funds.